

BIOMARIN PHARMACEUTICAL INC

Form 4

April 04, 2008

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
BAFFI ROBERT

(Last) (First) (Middle)

**C/O BIOMARIN
PHARMACEUTICAL INC., 105
DIGITAL DRIVE**

(Street)

NOVATO, CA 94949

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading
Symbol

**BIOMARIN PHARMACEUTICAL
INC [BMRN]**

3. Date of Earliest Transaction
(Month/Day/Year)
04/02/2008

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____ 10% Owner
____X____ Officer (give title below) ____ Other (specify below)
SVP, Technical Operations

6. Individual or Joint/Group Filing(Check
Applicable Line)
____X____ Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price		
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	M		23,762	A	\$ 7.76	58,442	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	M		15,000	A	\$ 6.13	73,442	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S		900	D	\$ 36.66	72,542	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S		575	D	\$ 36.69	71,967	D
	04/02/2008 ⁽¹⁾	04/02/2008	S		125	D	\$ 36.7	71,842	D

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock								
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	100	D	\$ 36.71	71,742	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	1,300	D	\$ 36.72	70,442	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	100	D	\$ 36.76	70,342	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	100	D	\$ 36.765	70,242	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	1,361	D	\$ 36.8	68,881	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	500	D	\$ 36.802	68,381	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	1,280	D	\$ 36.81	67,101	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	900	D	\$ 36.82	66,201	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	539	D	\$ 36.83	65,662	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	320	D	\$ 36.84	65,342	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	950	D	\$ 36.85	64,392	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	900	D	\$ 36.86	63,492	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	583	D	\$ 36.87	62,909	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	100	D	\$ 36.8875	62,809	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	1,929	D	\$ 36.9	60,880	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	300	D	\$ 36.92	60,580	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	100	D	\$ 36.9225	60,480	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	303	D	\$ 36.94	60,177	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	1,300	D	\$ 36.95	58,877	D
	04/02/2008 ⁽¹⁾	04/02/2008	S	1,200	D	\$ 36.96	57,677	D

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common
Stock

Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	1,200	D	\$ 36.97	56,477	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	1,400	D	\$ 36.98	55,077	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	1,300	D	\$ 36.99	53,777	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	1,900	D	\$ 37	51,877	D
Common Stock	04/02/2008 ⁽¹⁾	04/02/2008	S	1,400	D	\$ 37.01	50,477	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Stock Option (right to buy)	\$ 7.76	04/02/2008 ⁽¹⁾	04/02/2008	M	23,762	06/30/2004 ⁽²⁾ 12/30/2013	Common Stock 23,762
Stock Option (right to buy)	\$ 6.13	04/02/2008 ⁽¹⁾	04/02/2008	M	15,000	07/07/2005 ⁽³⁾ 01/06/2015	Common Stock 15,000

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Reporting Owners

BAFFI ROBERT
C/O BIOMARIN PHARMACEUTICAL INC.
105 DIGITAL DRIVE
NOVATO, CA 94949

SVP, Technical Operations

Signatures

/s/ G. Eric Davis,
Attorney-in-Fact

04/04/2008

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a Rule 10b5-1 Trading Plan.
 - (2) Original option grant vested 6/48ths on 6/30/04, and 1/48th on the 31st of every month thereafter.
 - (3) Original option grant vested 6/48ths on 7/7/05, and 1/48th on the 7th of every month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.